We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Rheumatology

Journal Scan / Research · July 20, 2022

Effectiveness of TNF Inhibitors, Abatacept, IL-6 Inhibitors, and JAK Inhibitors in the Treatment of Rheumatoid Arthritis

Annals of the Rheumatic Diseases

 

Additional Info

Annals of the Rheumatic Diseases
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration
Ann. Rheum. Dis 2022 Jun 15;[EPub Ahead of Print], K Lauper, M Iudici, D Mongin, SA Bergstra, D Choquette, C Codreanu, R Cordtz, D De Cock, L Dreyer, O Elkayam, EM Hauge, D Huschek, KL Hyrich, F Iannone, N Inanc, L Kearsley-Fleet, EK Kristianslund, TK Kvien, BF Leeb, G Lukina, DC Nordström, K Pavelka, M Pombo-Suarez, Z Rotar, MJ Santos, A Strangfeld, P Verschueren, DS Courvoisier, A Finckh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading